Top

Published in:

Open Access 01-12-2011 | Review

Efficacy of lifestyle interventions in physical health management of patients with severe mental illness

Authors: Fernando Chacón, Fernando Mora, Alicia Gervás-Ríos, Inmaculada Gilaberte

Published in: Annals of General Psychiatry | Issue 1/2011

Abstract

Awareness of the importance of maintaining physical health for patients with severe mental illnesses has recently been on the increase. Although there are several elements contributing to poor physical health among these patients as compared with the general population, risk factors for cardiovascular disease such as smoking, diabetes mellitus, hypertension, dyslipidemia, metabolic syndrome, and obesity are of particular significance due to their relationship with mortality and morbidity. These patients present higher vulnerability to cardiovascular risk factors based on several issues, such as genetic predisposition to certain pathologies, poor eating habits and sedentary lifestyles, high proportions of smokers and drug abusers, less access to regular health care services, and potential adverse events during pharmacological treatment. Nevertheless, there is ample scientific evidence supporting the benefits of lifestyle interventions based on diet and exercise designed to minimize and reduce the negative impact of these risk factors on the physical health of patients with severe mental illnesses.

Available only for authorised users

Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, Hennekens CH, Lambert M, Leucht S, Maj M, McIntyre RS, Naber D, Newcomer JW, Olfson M, Osby U, Sartorius N, Lieberman JA: Cormorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry. 2008, 69: 514-519. 10.4088/JCP.v69n0401.PubMed

Laursen TM, Munk-Olsen T, Agerbo E, Gasse C, Mortensen PB: Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry. 2009, 66: 713-720. 10.1001/archgenpsychiatry.2009.61.PubMed

Leucht S, Burkard T, Henderson J, Maj M, Sartorius N: Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand. 2007, 116: 317-333. 10.1111/j.1600-0447.2007.01095.x.PubMed

Surtees PG, Wainwright NW, Luben RN, Wareham NJ, Bingham SA, Khaw KT: Depression and ischemic heart disease mortality: evidence from the EPIC-Norfolk United Kingdom prospective cohort study. Am J Psychiatry. 2008, 165: 515-523. 10.1176/appi.ajp.2007.07061018.PubMed

Piatt EE, Munetz MR, Ritter C: An examination of premature mortality among decedents with serious mental illness and those in the general population. Psychiatr Serv. 2010, 61: 663-668. 10.1176/appi.ps.61.7.663.PubMed

Dickey B, Normand SL, Weiss RD, Drake RE, Azeni H: Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv. 2002, 53: 861-867. 10.1176/appi.ps.53.7.861.PubMed

Hasnain M, Vieweg WV, Fredrickson SK, Beatty-Brooks M, Fernandez A, Pandurangi AK: Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Prim Care Diabetes. 2009, 3: 5-15. 10.1016/j.pcd.2008.10.005.PubMed

Bellivier F: Schizophrenia, antipsychotics and diabetes: genetic aspects. Eur Psychiatry. 2005, 20 (Suppl 4): S335-S339.PubMed

Gough SC, O'Donovan MC: Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?. J Psychopharmacol. 2005, 19 (Suppl): 47-55. 10.1177/0269881105058380.PubMed

10.

Phelan M, Stradins L, Morrison S: Physical health of people with severe mental illness. BMJ. 2001, 322: 443-444. 10.1136/bmj.322.7284.443.PubMedCentralPubMed

11.

Maj M: Necesidad de proteger y fomentar la salud física en personas con enfermedad mental grave. Rev Psiquiatr Salud Ment (Barc). 2009, 2: 1-4. 10.1016/S1888-9891(09)70709-8.

12.

Green AI, Drake RE, Brunette MF, Noordsy DL: Schizophrenia and co-occurring substance use disorder. Am J Psychiatry. 2007, 164: 402-408. 10.1176/appi.ajp.164.3.402.PubMed

13.

Green AI, Brown ES: Comorbid schizophrenia and substance abuse. J Clin Psychiatry. 2006, 67: e08-10.4088/JCP.0906e08.PubMed

14.

Goff DC, Cather C, Evins AE, Henderson DC, Freudenreich O, Copeland PM, Bierer M, Duckworth K, Sacks FM: Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005, 66: 183-194. 10.4088/JCP.v66n0205.PubMed

15.

Marwaha S, Johnson S, Bebbington P, Angermeyer MC, Brugha T, Azorin JM, Kilian R, Kornfeld A, Toumi M, EuroSC Study Group: Correlates of subjective quality of life in people with schizophrenia: findings from the EuroSC study. J Nerv Ment Dis. 2008, 196: 87-94. 10.1097/NMD.0b013e318162aa9c.PubMed

16.

Sáiz Ruiz J, Bobes García J, Vallejo Ruiloba J, Giner Ubago J, García-Portilla González MP, Grupo de Trabajo sobre la Salud Física del Paciente con Esquizofrenia: Consensus on physical health of patients with schizophrenia from the Spanish Societies of Psychiatry and Biological Psychiatry [in Spanish]. Actas Esp Psiquiatr. 2008, 36: 251-264.PubMed

17.

Haddad PM, Sharma SG: Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007, 21: 911-936. 10.2165/00023210-200721110-00004.PubMed

18.

Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S: Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010, 123: 225-233. 10.1016/j.schres.2010.07.012.PubMedCentralPubMed

19.

Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE, EUFEST study group: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008, 371: 1085-1097. 10.1016/S0140-6736(08)60486-9.PubMed

20.

Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, Ramirez-Bonilla ML, Alvarez-Jimenez M, Pelayo-Teran JM, Garcia-Unzueta MT, Amado JA, Vazquez-Barquero JL: Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. Schizophr Res. 2008, 99: 13-22. 10.1016/j.schres.2007.10.022.PubMed

21.

Perez-Iglesias R, Mata I, Pelayo-Teran JM, Amado JA, Garcia-Unzueta MT, Berja A, Martinez-Garcia O, Vazquez-Barquero JL, Crespo-Facorro B: Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. Schizophr Res. 2009, 107: 115-121. 10.1016/j.schres.2008.09.028.PubMed

22.

Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, Martinez-Garcia O, Vazquez-Barquero JL: A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry. 2007, 68: 1733-1740. 10.4088/JCP.v68n1113.PubMed

23.

Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, Lieberman J, Schooler NR: The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bul. 2002, 28: 5-16.

24.

American Psychiatric Association: Practice Guideline for Schizophrenia. 2004, Arlington, VA: American Psychiatric Association

25.

Bobes J, Ruiz JS, Montes JM, Mostaza J, Rico-Villademoros F, Vieta E: Consenso Español de Salud Física del Paciente con Trastorno Bipolar. Rev Psiquiatr Salud Ment. 2008, 1: 26-37. 10.1016/S1888-9891(08)72513-8.PubMed

26.

Fernandez-Egea E, Bernardo M, Heaphy CM, Griffith JK, Parellada E, Esmatjes E, Conget I, Nguyen L, George V, Stöppler H, Kirkpatrick B: Telomere length and pulse pressure in newly diagnosed, antipsychotic-naive patients with nonaffective psychosis. Schizophr Bull. 2009, 35: 437-442. 10.1093/schbul/sbn169.PubMedCentralPubMed

27.

Fernandez-Egea E, Bruna A, Garcia-Rizo C, Bernardo M, Kirkpatrick B: Stem cell signaling in newly diagnosed, antipsychotic-naive subjects with nonaffective psychosis. Mol Psychiatry. 2009, 14: 989-991. 10.1038/mp.2009.45.PubMedCentralPubMed

28.

De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ: Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009, 24: 412-424. 10.1016/j.eurpsy.2009.01.005.PubMed

29.

Brown AD, Barton DA, Lambert GW: Cardiovascular abnormalities in patients with major depressive disorder: autonomic mechanisms and implications for treatment. CNS Drugs. 2009, 23: 583-602. 10.2165/00023210-200923070-00004.PubMed

30.

Stahl SM, Mignon L, Meyer JM: Which comes first: atypical antipsychotic treatment or cardiometabolic risk?. Acta Psychiatr Scand. 2009, 119: 171-179. 10.1111/j.1600-0447.2008.01334.x.PubMed

31.

Auquier P, Lançon C, Rouillon F, Lader M, Holmes C: Mortality in schizophrenia. Pharmacoepidemiol Drug Saf. 2006, 15: 873-879. 10.1002/pds.1325.PubMed

32.

Hennekens CH, Hennekens AR, Hollar D, Casey DE: Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005, 150: 1115-1121. 10.1016/j.ahj.2005.02.007.PubMed

33.

De Hert M, Peuskens J, van Winkel R: Mortality in patients with schizophrenia. Lancet. 2009, 374: 1591-PubMed

34.

Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, Baker TB: A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry. 2009, 66: 1253-1262. 10.1001/archgenpsychiatry.2009.142.PubMedCentralPubMed

35.

Campbell RK: Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies. J Am Pharm Assoc. 2009, 49 (Suppl 1): S3-S9.

36.

Germino FW: The management and treatment of hypertension. Clin Cornerstone. 2009, 9 (Suppl 3): S27-S33.PubMed

37.

Garg A, Simha V: Update on dyslipidemia. J Clin Endocrinol Metab. 2007, 92: 1581-1589. 10.1210/jc.2007-0275.PubMed

38.

Foster-Schubert KE, Cummings DE: Emerging therapeutic strategies for obesity. Endocr Rev. 2006, 27: 779-793.PubMed

39.

Citrome L, Jaffe A, Levine J, Martello D: Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004. Psychiatr Serv. 2006, 57: 1132-1139. 10.1176/appi.ps.57.8.1132.PubMed

40.

Holt RI, Peveler RC: Association between antipsychotic drugs and diabetes. Diabetes Obes Metab. 2006, 8: 125-135. 10.1111/j.1463-1326.2005.00495.x.PubMed

41.

Kantrowitz JT, Citrome L: Olanzapine: review of safety 2008. Expert Opin Drug Saf. 2008, 7: 761-769. 10.1517/14740330802423234.PubMed

42.

von Hausswolff-Juhlin Y, Bjartveit M, Lindström E, Jones P: Schizophrenia and physical health problems. Acta Psychiatr Scand Suppl. 2009, 438: 15-21.PubMed

43.

Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV: Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord. 2002, 70: 19-26. 10.1016/S0165-0327(01)00456-6.PubMed

44.

Holt RI, Peveler RC, Byrne CD: Schizophrenia, the metabolic syndrome and diabetes. Diabet Med. 2004, 21: 515-523. 10.1111/j.1464-5491.2004.01199.x.PubMed

45.

McIntyre RS, Konarski JZ, Misener VL, Kennedy SH: Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry. 2005, 17: 83-93. 10.1080/10401230590932380.PubMed

46.

Johannessen L, Strudsholm U, Foldager L, Munk-Jørgensen P: Increased risk of hypertension in patients with bipolar disorder and patients with anxiety compared to background population and patients with schizophrenia. J Affect Disord. 2006, 95: 13-17. 10.1016/j.jad.2006.03.027.PubMed

47.

Osborn DP, Wright CA, Levy G, King MB, Deo R, Nazareth I: Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis. BMC Psychiatry. 2008, 8: 84-10.1186/1471-244X-8-84.PubMedCentralPubMed

48.

Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S: Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004, 161: 1334-1349. 10.1176/appi.ajp.161.8.1334.PubMed

49.

Bernardo M, Cañas F, Banegas JR, Casademont J, Riesgo Y, Varela C, RICAVA Study Group: Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: a cross-sectional study in a low cardiovascular disease risk geographical area. Eur Psychiatry. 2009, 24: 431-441. 10.1016/j.eurpsy.2009.07.010.PubMed

50.

Aranceta J, Moreno B, Moya M, Anadón A: Prevention of overweight and obesity from a public health perspective. Nutr Rev. 2009, 67 (Suppl 1): S83-S8.PubMed

51.

Daumit GL, Clark JM, Steinwachs DM, Graham CM, Lehman A, Ford DE: Prevalence and correlates of obesity in a community sample of individuals with severe and persistent mental illness. J Nerv Ment Dis. 2003, 191: 799-805. 10.1097/01.nmd.0000100923.20188.2d.PubMed

52.

Loh C, Meyer JM, Leckband SG: A comprehensive review of behavioral interventions for weight management in schizophrenia. Ann Clin Psychiatry. 2006, 18: 23-31.PubMed

53.

Reist C, Mintz J, Albers LJ, Jamal MM, Szabo S, Ozdemir V: Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002. J Clin Psychopharmacol. 2007, 27: 46-51. 10.1097/JCP.0b013e31802e5126.PubMed

54.

Alvarez-Jiménez M, Hetrick SE, González-Blanch C, Gleeson JF, McGorry PD: Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2008, 193: 101-107. 10.1192/bjp.bp.107.042853.PubMed

55.

Gentile S: Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications. Obes Rev. 2009, 10: 527-542. 10.1111/j.1467-789X.2009.00589.x.PubMed

56.

Baptista T, ElFakih Y, Uzcátegui E, Sandia I, Tálamo E, Araujo de Baptista E, Beaulieu S: Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs. 2008, 22: 477-495. 10.2165/00023210-200822060-00003.PubMed

57.

Brown WV, Fujioka K, Wilson PW, Woodworth KA: Obesity: why be concerned?. Am J Med. 2009, 122 (Suppl 1): S4-S11.PubMed

58.

Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH: The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009, 9: 88-10.1186/1471-2458-9-88.PubMedCentralPubMed

59.

Bresee LC, Majumdar SR, Patten SB, Johnson JA: Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res. 2010, 117: 75-82. 10.1016/j.schres.2009.12.016.PubMed

60.

Meyer JM, Stahl SM: The metabolic syndrome and schizophrenia. Acta Psychiatr Scand. 2009, 119: 4-14. 10.1111/j.1600-0447.2008.01317.x.PubMed

61.

Lin CC, Liu CS, Li CI, Lin WY, Lai MM, Lin T, Chang PC, Lee YD, Chen CC, Lin CH, Yang CW, Hsiao CY, Chen W, Li TC: The relation of metabolic syndrome according to five definitions to cardiovascular risk factors - a population-based study. BMC Public Health. 2009, 9: 484-10.1186/1471-2458-9-484.PubMedCentralPubMed

62.

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC, International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120: 1640-1645. 10.1161/CIRCULATIONAHA.109.192644.PubMed

63.

Misra A, Khurana L: Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab. 2008, 93 (Suppl 1): S9-S30.PubMed

64.

Fagiolini A, Goracci A: The effects of undertreated chronic medical illnesses in patients with severe mental disorders. J Clin Psychiatry. 2009, 70 (Suppl 3): 22-29. 10.4088/JCP.7075su1c.04.PubMed

65.

Newcomer JW: Metabolic syndrome and mental illness. Am J Manag Care. 2007, 13 (Suppl): S170-S177.PubMed

66.

Fagerström K, Aubin HJ: Management of smoking cessation in patients with psychiatric disorders. Curr Med Res Opin. 2009, 25: 511-518. 10.1185/03007990802707568.PubMed

67.

Siru R, Hulse GK, Tait RJ: Assessing motivation to quit smoking in people with mental illness: a review. Addiction. 2009, 104: 719-733. 10.1111/j.1360-0443.2009.02545.x.PubMed

68.

Fleming P, Godwin M: Lifestyle interventions in primary care: systematic review of randomized controlled trials. Can Fam Physician. 2008, 54: 1706-1713.PubMedCentralPubMed

69.

Demark-Wahnefried W, Jones LW: Promoting a healthy lifestyle among cancer survivors. Hematol Oncol Clin North Am. 2008, 22: 319-342. 10.1016/j.hoc.2008.01.012.PubMedCentralPubMed

70.

Brown T, Avenell A, Edmunds LD, Moore H, Whittaker V, Avery L, Summerbell C: Systematic review of long-term lifestyle interventions to prevent weight gain and morbidity in adults. Obes Rev. 2009, 10: 627-638. 10.1111/j.1467-789X.2009.00641.x.PubMed

71.

Madden SG, Loeb SJ, Smith CA: An integrative literature review of lifestyle interventions for the prevention of type II diabetes mellitus. J Clin Nurs. 2008, 17: 2243-2256. 10.1111/j.1365-2702.2008.02335.x.PubMed

72.

Grundy SM: Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient?. Am J Med. 2007, 120 (Suppl 1): S3-8.PubMed

73.

Vadstrup ES, Frølich A, Perrild H, Borg E, Røder M: Lifestyle intervention for type 2 diabetes patients: trial protocol of The Copenhagen Type 2 Diabetes Rehabilitation Project. BMC Public Health. 2009, 9: 166-10.1186/1471-2458-9-166.PubMedCentralPubMed

74.

Magkos F, Yannakoulia M, Chan JL, Mantzoros CS: Management of the metabolic syndrome and type 2 diabetes through lifestyle modification. Annu Rev Nutr. 2009, 29: 223-256. 10.1146/annurev-nutr-080508-141200.PubMed

75.

Eriksson KF, Lindgärde F: Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia. 1991, 34: 891-898. 10.1007/BF00400196.PubMed

76.

Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001, 344: 1343-1350. 10.1056/NEJM200105033441801.PubMed

77.

Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, He YQ, Liu YJ, Chen JD, Li LH: Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008, 299: 185-193. 10.1001/jama.2007.56-b.PubMed

78.

Tuomilehto J: Nonpharmacologic therapy and exercise in the prevention of type 2 diabetes. Diabetes Care. 2009, 32 (Suppl 2): S189-S193.PubMedCentralPubMed

79.

Maruthur NM, Wang NY, Appel LJ: Lifestyle interventions reduce coronary heart disease risk: results from the PREMIER Trial. Circulation. 2009, 119: 2026-2031. 10.1161/CIRCULATIONAHA.108.809491.PubMedCentralPubMed

80.

Aucott L, Rothnie H, McIntyre L, Thapa M, Waweru C, Gray D: Long-term weight loss from lifestyle intervention benefits blood pressure? A systematic review. Hypertension. 2009, 54: 756-762. 10.1161/HYPERTENSIONAHA.109.135178.PubMed

81.

Smith S, Yeomans D, Bushe CJ, Eriksson C, Harrison T, Holmes R, Mynors-Wallis L, Oatway H, Sullivan G: A well-being programme in severe mental illness. Reducing risk for physical ill-health: a post-programme service evaluation at 2 years. Eur Psychiatry. 2007, 22: 413-418. 10.1016/j.eurpsy.2007.07.002.PubMed

82.

Pendlebury J, Haddad P, Dursun S: Evaluation of a behavioural weight management programme for patients with severe mental illness: 3 year results. Hum Psychopharmacol. 2005, 20: 447-448. 10.1002/hup.707.PubMed

83.

Vreeland B, Minsky S, Menza M, Rigassio Radler D, Roemheld-Hamm B, Stern R: A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv. 2003, 54: 1155-1157. 10.1176/appi.ps.54.8.1155.PubMed

84.

Poole Hoffmann V, Bushe C, Meyers AL, Greenwood T, Benzing L, Ahl J: A wellness intervention program for patients with mental illness: self-reported outcomes. Prim Care Companion J Clin Psychiatry. 2008, 10: 329-331. 10.4088/PCC.v10n0411c.PubMedCentralPubMed

85.

Hoffmann VP, Ahl J, Meyers A, Schuh L, Shults KS, Collins DM, Jensen L: Wellness intervention for patients with serious and persistent mental illness. J Clin Psychiatry. 2005, 66: 1576-1579. 10.4088/JCP.v66n1213.PubMed

86.

Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG: The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh. 2003, 35: 237-241. 10.1111/j.1547-5069.2003.00237.x.PubMed

87.

Bushe CJ, McNamara D, Haley C, McCrossan MF, Devitt P: Weight management in a cohort of Irish inpatients with serious mental illness (SMI) using a modular behavioural programme. A preliminary service evaluation. BMC Psychiatry. 2008, 8: 76-10.1186/1471-244X-8-76.PubMedCentralPubMed

88.

Kwon JS, Choi JS, Bahk WM, Yoon Kim C, Hyung Kim C, Chul Shin Y, Park BJ, Geun Oh C: Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial. J Clin Psychiatry. 2006, 67: 547-553. 10.4088/JCP.v67n0405.PubMed

89.

Lee SJ, Choi EJ, Kwon JS: A naturalistic multicenter trial of a 12-week weight management program for overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2008, 69: 555-562. 10.4088/JCP.v69n0406.PubMed

90.

Pendlebury J, Bushe CJ, Wildgust HJ, Holt RI: Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK. Acta Psychiatr Scand. 2007, 115: 286-294. 10.1111/j.1600-0447.2006.00906.x.PubMed

91.

Holt RI, Pendlebury J, Wildgust HJ, Bushe CJ: Intentional weight loss in overweight and obese patients with severe mental illness: 8-year experience of a behavioral treatment program. J Clin Psychiatry. 2010, 71: 800-805. 10.4088/JCP.09m05627gre.PubMed

92.

Poulin MJ, Chaput JP, Simard V, Vincent P, Bernier J, Gauthier Y, Lanctôt G, Saindon J, Vincent A, Gagnon S, Tremblay A: Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Aust N Z J Psychiatry. 2007, 41: 980-989. 10.1080/00048670701689428.PubMed

93.

Bushe C, Haddad P, Peveler R, Pendlebury J: The role of lifestyle interventions and weight management in schizophrenia. J Psychopharmacol. 2005, 19 (Suppl): 28-35. 10.1177/0269881105058682.PubMed

94.

McKibbin CL, Patterson TL, Norman G, Patrick K, Jin H, Roesch S, Mudaliar S, Barrio C, O'Hanlon K, Griver K, Sirkin A, Jeste DV: A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial. Schizophr Res. 2006, 86: 36-44. 10.1016/j.schres.2006.05.010. Epub 2006 Jul 12PubMed

95.

Camhi SM, Stefanick ML, Katzmarzyk PT, Young DR: Metabolic syndrome and changes in body fat from a low-fat diet and/or exercise randomized controlled trial. Obesity (Silver Spring). 2010, 18: 548-554. 10.1038/oby.2009.304.

96.

ter Bogt NC, Bemelmans WJ, Beltman FW, Broer J, Smit AJ, van der Meer K: Preventing weight gain: one-year results of a randomized lifestyle intervention. Am J Prev Med. 2009, 37: 270-277. 10.1016/j.amepre.2009.06.011.PubMed

97.

Weinberger AH, Hitsman B, Papandonatos GD, Sacco KA, Vessicchio JC, George TP: Predictors of abstinence and changes in psychiatric symptoms in a pooled sample of smokers with schizophrenia receiving combination pharmacotherapy and behavioral therapy for smoking cessation. J Clin Psychopharmacol. 2009, 29: 601-603. 10.1097/JCP.0b013e3181bfd0b4.PubMedCentralPubMed

98.

Bradshaw T, Lovell K, Harris N: Healthy living interventions and schizophrenia: a systematic review. J Adv Nurs. 2005, 49: 634-654. 10.1111/j.1365-2648.2004.03338.x.PubMed

99.

George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, Rounsaville BJ, Kosten TR: Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000, 157: 1835-1842. 10.1176/appi.ajp.157.11.1835.PubMed

100.

El-Guebaly N, Cathcart J, Currie S, Brown D, Gloster S: Smoking cessation approaches for persons with mental illness or addictive disorders. Psychiatr Serv. 2002, 53: 1166-1170. 10.1176/appi.ps.53.9.1166.PubMed

101.

Rigotti NA, Munafo MR, Stead LF: Smoking cessation interventions for hospitalized smokers: a systematic review. Arch Intern Med. 2008, 168: 1950-1960. 10.1001/archinte.168.18.1950.PubMedCentralPubMed

Title: Efficacy of lifestyle interventions in physical health management of patients with severe mental illness
Authors: Fernando Chacón
Fernando Mora
Alicia Gervás-Ríos
Inmaculada Gilaberte
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Annals of General Psychiatry / Issue 1/2011
Electronic ISSN: 1744-859X
DOI: https://doi.org/10.1186/1744-859X-10-22

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Efficacy of lifestyle interventions in physical health management of patients with severe mental illness

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Hearing impairment and cognitive function among a community-dwelling population in Japan

Chemical restraint in routine clinical practice: a report from a general hospital psychiatric ward in Greece

Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts?

Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial

Disability and health-related quality of life in outpatients with generalised anxiety disorder treated in psychiatric clinics: is there still room for improvement?

Prolonged apnea during electroconvulsive therapy in monozygotic twins: case reports